Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Mgmt Meeting Takeaways: FDA Desire to Use 505(j) for M356
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $17.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone, biosimilars potential, modest m-enox revenue stream. The stay on the enox injunction returned the m-enox revenue to a modest royalty stream to MNTA. We expect progress on biosimilars candidates from the Baxter (NYSE: BAX) deal in 2012/2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
"M356: MNTA new positive clarity for generic Copaxone 505(j) review. MNTA is “pleased” with its dialog with FDA, saying FDA stated a preference for the 505(j) path for M356 review..."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.45 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone, biosimilars potential, modest m-enox revenue stream. The stay on the enox injunction returned the m-enox revenue to a modest royalty stream to MNTA. We expect progress on biosimilars candidates from the Baxter (NYSE: BAX) deal in 2012/2013. We expect the generic Copaxone suit to resolve in MNTA’s favor mid-2012."
"M356: MNTA new positive clarity for generic Copaxone 505(j) review. MNTA is “pleased” with its dialog with FDA, saying FDA stated a preference for the 505(j) path for M356 review..."
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $15.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
